InMed Pharmaceuticals (INM) risk factors

78 risks, 5 new, 2 reworded since the prior year. Merger execution, litigation, and failure to complete the transaction now dominate the risk disclosures.

73 risks, 2 new, 5 dropped, 8 reworded since the prior year. New U.S. tariffs and global trade conflicts create macroeconomic uncertainty for operations.

76 risks. InMed Pharmaceuticals faces early-stage clinical trial risks and Nasdaq delisting threats due to minimum bid price requirements. The company relies heavily on its proprietary IntegraSyn manufacturing approach and EB disease indications. Regulatory approval processes across the FDA, HC, and EMA remain lengthy and uncertain.